{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Rigel Pharmaceuticals, Inc.
Is Rigel Pharmaceuticals, Inc. overvalued or undervalued?
As of September 12, 2025, Rigel Pharmaceuticals is considered very attractive due to its undervalued P/E ratio of 10, a low PEG ratio of 0.01, and strong performance with a 157.59% return over the past year, significantly outperforming the S&P 500.
Rigel Pharmaceuticals Sees Valuation Upgrade Amid Strong Financial Performance and Growth
Rigel Pharmaceuticals, Inc. has experienced a significant evaluation adjustment, moving to a very attractive valuation grade. Key financial metrics include a P/E ratio of 10, a high Return on Capital Employed of 2630.60%, and impressive net profit growth of 420.82%, reflecting strong operational performance and stability.
Rigel Pharmaceuticals Experiences Valuation Adjustment Amid Strong Financial Metrics and Market Position
Rigel Pharmaceuticals, Inc. has adjusted its valuation, showcasing strong financial metrics such as a P/E ratio of 10 and a high return on capital employed at 2630.60%. Compared to peers, Rigel presents a more favorable valuation profile, with significant year-to-date and one-year returns outperforming the S&P 500.
Rigel Pharmaceuticals Achieves 172.26% Return, Marking It as a Multibagger in Biotechnology Sector
Rigel Pharmaceuticals, Inc. has recently undergone a revision in its score, reflecting its strong financial performance and market position. Despite a minor decline in stock price, the company has achieved remarkable year-to-date returns and impressive growth in net profit, underscoring its resilience and operational efficiency in the competitive pharmaceuticals sector.
Is Rigel Pharmaceuticals, Inc. overvalued or undervalued?
As of March 4, 2025, Rigel Pharmaceuticals is considered very attractive due to its undervalued status with a P/E ratio of 10, a low PEG ratio of 0.01, strong growth potential, and impressive returns, despite a recent stock price decline.
Is Rigel Pharmaceuticals, Inc. technically bullish or bearish?
As of June 20, 2025, Rigel Pharmaceuticals, Inc. shows a mildly bullish trend, supported by daily moving averages and monthly MACD, but tempered by weekly MACD and Bollinger Bands indicating bearish signals, suggesting cautious bullish sentiment with potential volatility.
Who are in the management team of Rigel Pharmaceuticals, Inc.?
As of March 2022, the management team of Rigel Pharmaceuticals, Inc. is led by Mr. Raul Rodriguez as President and CEO, supported by independent directors including Mr. Bradford Goodwin, Mr. Keith Katkin, Dr. Brian Kotzin, Mr. Gregg Lapointe, and Mr. Gary Lyons.
What does Rigel Pharmaceuticals, Inc. do?
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing small molecule drugs for immune and hematological disorders, cancer, and rare diseases. As of March 2025, it reported net sales of $53 million and a market cap of $342.44 million.
How big is Rigel Pharmaceuticals, Inc.?
As of Jun 18, Rigel Pharmaceuticals, Inc. has a market capitalization of 342.44 million and reported net sales of 203.08 million with a net profit of 37.18 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
